The first company to begin human clinical trials of its coronavirus vaccine candidate in the United States — Moderna — has once again come up with encouraging study data relating to mRNA-1273.

Novavax (NVAX) is a formidable name in the list of companies who are working on a vaccine. The company’s shares have gained 2487.4% this year. Let’s look at ETFs with the highest exposure to Novarax that can gain on the positive development,

The competition to come up with a coronavirus vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to Moderna.

The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to the biotech sector:

The first company to start human clinical trials of its coronavirus vaccine candidate in the United States — Moderna — has informed that it is on schedule to initiate the final-stage clinical trial by July.

Given rising spending on drugs and healthcare all over the world, investors should tap the opportune moment by investing in the biotech sector.

Instead of trying to pick winners from the virus, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and healthcare all over the world.

Although the coronavirus seems to be opening up opportunities for biotech companies, it is dampening their guidance as well. Despite impressive results, most of these biotechs have been seeing declining share prices since the earnings releases.

Biotech ETFs are surging with many hitting new 52-week highs lately.

Here's a look at the industries and groups most like to move the most this month, for better or for worse.

The healthcare space is witnessing a wave of mergers and acquisitions, which could change the landscape of the healthcare business.

Though the biotech sector is down in October, it shows promise for the long-term due to a wave of mergers & acquisitions and a positive regulatory backdrop.

The biotech sector has been performing remarkably well driven by a wave of mergers and acquisitions, new tax legislation, and a positive regulatory backdrop. Strong Q2 earnings results have added to the strength as biotech giants topped estimates.

The earnings season is off to a flying start, owing to a slew of upbeat economic data, strong corporate performance, and President Donald Trump's tax reform signed into law.

The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter.

The earnings season is off to a flying start with equity markets. However, the performance has been a mixed bag for biotech companies with some beating market expectations, while a few failed to do so.